Asthma and COPD Therapies Forecast 2014 2024

download Asthma and COPD Therapies Forecast 2014 2024

of 23

  • date post

    25-May-2015
  • Category

    Business

  • view

    1.823
  • download

    3

Embed Size (px)

description

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1338/Asthma-and-COPD-Therapies-Market-Forecast-2014-2024

Transcript of Asthma and COPD Therapies Forecast 2014 2024

  • 1. Contents1. Report Overview1. Report Overview1.1 Global Asthma and COPD Therapies Market Overview1.2 Global Asthma and COPD Therapies Market Segmentation1.3 Why You Should Read This Report1.4 How This Report Delivers1.5 Key Questions Answered by This Analytical Report1.6 Who is This Report For?1.7 Methodology1.8 Frequently Asked Questions (FAQ)1.9 Associated Visiongain Reports1.10 About Visiongain2. Introduction to Asthma and COPD Therapies2. Introduction to Asthma and COPD Therapies2.1 The Pharmaceutical Industry: a Very Brief Overview2.2 Overview of Respiratory Diseases2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive2.3 What is Asthma?2.3.1 Trends in Asthma Prevalence2.3.2 Pathophysiology of Asthma2.3.3 Symptoms of Asthma2.3.4 Causes and Triggers for Asthma2.3.5 Treatment of Asthma2.3.6 Guidelines for Asthma Treatmentwww.visiongain.com

2. Contents2.3.7 Drug Treatments for Asthma2.3.8 Drug Delivery Methods in Asthma2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?2.4.1 Trends in COPD Prevalence2.4.2 Pathophysiology of COPD2.4.3 Signs and Symptoms of COPD2.4.4 Treatment of COPD2.4.5 Drug Treatments for COPD2.4.6 Guidelines for COPD Treatment2.5 Major Drug Classes in the Treatment of Asthma and COPD2.5.1 Bronchodilators2.5.1.1 Beta2-Agonists2.5.1.2 Anticholinergics2.5.2 Anti-Inflammatory Drugs2.5.2.1 Corticosteroids2.5.2.2 Leukotriene Receptor Antagonists2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease2.5.3 Combination Drugs2.5.4 Drugs for Allergic Rhinitis2.6 Phases of Clinical Trials2.7 Scope of this Report2.8 Currency Exchange Rates in This Reportwww.visiongain.com 3. Contents3. Asthma and COPD Therapies: World Market 2014-20243. Asthma and COPD Therapies: World Market 2014-20243.1 The World Respiratory Drugs Market by Therapeutic Area3.2 The World Asthma and COPD Therapies Market in 20133.2.1 Leading Asthma and COPD Therapies3.2.2 Leading Companies in the Asthma and COPD Therapies Market3.3 World Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2014-20243.3.1 World Asthma Therapies Market: Sales Forecast 2014-20243.3.2 World COPD Therapies Market: Sales Forecast 2014-20243.4 World Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2014-20243.5 Combination Drugs Lead the Asthma and COPD Therapies Market3.6 How Will Segmental Market Shares Change to 2024?3.6.1 World Asthma and COPD Therapies Market: Drivers and Restraints 2014-20243.7 Asthma and COPD Therapies: Trends and Developments3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?4. Leading National Markets 2014-20244. Leading National Markets 2014-20244.1 Regional Breakdown of the World Asthma and COPD Therapies Market4.2 World Asthma and COPD Therapies Market: Regional Forecast 2014-20244.2.1 How Will Regional Market Shares Change to 2024?4.3 National Breakdown of the World Asthma and COPD Therapies Market4.4 World Asthma and COPD Therapies Market: National Markets Forecast 2014-20244.4.1 How Will National Market Shares Change to 2024?www.visiongain.com 4. Contents4.5 The US Asthma and COPD Therapies Market 2014-20244.5.1 US Asthma and COPD Therapies Market Forecast 2014-20244.5.2 US Asthma and COPD Therapies Market: Trends and Developments4.5.2.1 Increasing COPD Prevalence in the US4.5.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence4.5.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair4.6 Japanese Asthma and COPD Therapies Market 2014-20244.6.1 Japanese Asthma and COPD Therapies Market Forecast 2014-20244.6.2 Japanese Asthma and COPD Therapies Market: Trends and Developments4.6.2.1 Generic Penetration to Reach 60% by 2018?4.6.2.2 Japanese Pharmaceutical Industry Regulatory Reform4.7 EU5 Asthma and COPD Therapies Market 2014-20244.7.1 German Asthma and COPD Therapies Market Forecast 2014-20244.7.2 French Asthma and COPD Therapies Market Forecast 2014-20244.7.3 UK Asthma and COPD Therapies Market Forecast 2014-20244.7.4 Italian Asthma and COPD Therapies Market Forecast 2014-20244.7.5 Spanish Asthma and COPD Therapies Market Forecast 2014-20244.7.6 EU5 Asthma and COPD Therapies Market: Trends and Developments4.7.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law4.7.6.2 France: Social Security Finance Bill 20144.7.6.3 UK: Improving Asthma and COPD Patient Outcomes4.7.6.4 Italy: Austerity Measures Limiting Growth4.7.6.5 Spain: The Start of Recovery in the Spanish Economy4.8 BRIC Asthma and COPD Therapies Market 2014-2024www.visiongain.com 5. Contents4.8.1 Chinese Asthma and COPD Therapies Market Forecast 2014-20244.8.2 Chinese Asthma and COPD Therapies Market: Trends and Developments4.8.2.1 Chinas Industrial Future and Asthma/COPD4.8.2.2 Expansion of Healthcare Coverage and Reimbursement4.8.2.3 Price Controls and the Anhui Model4.8.3 Brazilian Asthma and COPD Therapies Market Forecast 2014-20244.8.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments4.8.4.1 Increasing Access to Medicines4.8.5 Indian Asthma and COPD Therapies Market Forecast 2014-20244.8.6 Indian Asthma and COPD Therapies Market: Trends and Developments4.8.6.1 Drug Prices Control Order 20134.8.6.2 Expansion of Healthcare Provision4.8.7 Russian Asthma and COPD Therapies Market Forecast 2014-20244.8.8 Russian Asthma and COPD Therapies Market: Trends and Developments4.8.8.1 No Embargo on Foreign Drug Imports4.8.8.2 Pharma2020 and the Russian Pharmaceutical Industry4.9 Mexican Asthma and COPD Therapies Market 2014-20244.9.1 Mexican Asthma and COPD Therapies Market Forecast 2014-20244.9.2 Mexican Asthma and COPD Therapies Market: Trends and Developments4.9.2.1 Seguro Popular: Mexican Healthcare Reform4.9.2.2 COFEPRIS: Regulatory Changes and Improvements4.9.2.3 Mexicos Agreement for Innovationwww.visiongain.com 6. Contents5. Bronchodilator Monotherapy Market 2014-20245. Bronchodilator Monotherapy Market 2014-20245.1 Introduction to Bronchodilator Monotherapy5.2 The Bronchodilator Monotherapy Market in 20135.2.1 Leading Bronchodilators in 20135.3 Bronchodilator Monotherapy: Market Forecast 2014-20245.4 How Will Market Shares by Drug Class Change to 2024?5.5 The Short-Acting Beta2-Agonist (SABA) Market 2014-20245.5.1 Leading SABAs in 20135.5.2 SABAs: Market Forecast 2014-20245.5.3 Market Share of Leading SABAs to 20245.5.4 Ventolin (salbutamol, GSK)5.5.4.1 Ventolin: Sales Forecast 2014-20245.5.5 ProAir (salbutamol, Teva)5.5.5.1 ProAir: Sales Forecast 2014-20245.5.6 Proventil (salbutamol, Merck)5.5.6.1 Proventil: Sales Forecast 2014-20245.5.7 Xopenex (levosalbutamol, Dainippon Sumitomo)5.5.7.1 Xopenex: Sales Forecast 2014-20245.6 The Long-Acting Beta2-Agonist (LABA) Market 2014-20245.6.1 Leading LABAs in 20135.6.2 LABAs: Market Forecast 2014-20245.6.3 Market Share of Leading LABAs to 20245.6.4 Foradil (formoterol, Merck/Novartis)5.6.4.1 Foradil: Sales Forecast 2014-2024www.visiongain.com 7. Contents5.6.5 Serevent (salmeterol, GSK)5.6.5.1 Serevent: Sales Forecast 2014-20245.6.6 Arcapta/Onbrez (indacaterol, Novartis)5.6.6.1 Arcapta/Onbrez: Sales Forecast 2014-20245.6.7 Brovana (arfomoterol, Dainippon Sumitomo)5.6.7.1 Brovana: Sales Forecast 2014-20245.6.8 Striverdi (olodaterol, Boehringer Ingelheim)5.6.8.1 Striverdi: Sales Forecast 2014-20245.7 The Anticholinergics Market 2014-20245.7.1 Leading Anticholinergics in 20135.7.2 Anticholinergics: Market Forecast 2014-20245.7.3 Market Share of Leading Anticholinergics to 20245.7.4 Spiriva (tiotropium, Boehringer Ingelheim)5.7.4.1 Spiriva: Sales Forecast 2014-20245.7.5 Spiriva: Recent Developments5.7.5.1 Safety Concerns and the UPLIFT Trial5.7.5.2 Results of the POET Study5.7.5.3 Competition from Combination Products5.7.6 Atrovent (ipratropium, Boehringer Ingelheim)5.7.6.1 Atrovent: Sales Forecast 2014-20245.7.7 Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Forest/Menarini)5.7.7.1 Eklira/Tudorza/Bretaris: Sales Forecast 2014-2024www.visiongain.com 8. Contents6. Anti-Inflammatory Drugs Market 2014-20246. Anti-Inflammatory Drugs Market 2014-20246.1 Introduction to Anti-Inflammatory Drugs6.2 The Anti-Inflammatory Drugs Market in 20136.2.1 Leading Anti-Inflammatory Drugs in 20136.3 Anti-Inflammatory Drugs: Market Forecast 2014-20246.4 How Will Market Shares by Drug Class Change to 2024?6.5 The Corticosteroids Market 2014-20246.5.1 Leading Corticosteroids in 20136.5.2 Corticosteroids: Market Forecast 2014-20246.5.3 Market Share of Leading Corticosteroids to 20246.5.4 Flixotide/Flovent (fluticasone propionate, GSK)6.5.4.1 Flixotide/Flovent: Sales Forecast 2014-20246.5.5 Pulmicort (budesonide, AstraZeneca)6.5.5.1 Pulmicort: Sales Forecast 2014-20246.5.6 QVAR (beclometasone, Teva)6.5.6.1 QVAR: Sales Forecast 2014-20246.5.7 Asmanex (mometasone, Merck)6.5.7.1 Asmanex: Sales Forecast 2014-20246.6 The Anti-Leukotrienes Market 2014-20246.6.1 Leading Anti-Leukotrienes in 20136.6.2 Anti-Leukotrienes: Market Forecast 2014-20246.6.2.1 Market Share of Leading Anti-Leukotrienes to 20246.6.3 Singulair (montelukast, Merck)6.6.3.1 Singulair: Sales Forecast 2014-2024www.visiongain.com 9. Contents6.7 The Monoclonal Antibodies Market 2014-20246.7.1 Monoclonal Antibodies: Market Forecast 2014-20246.7.1.1 Market Share of Leading Monoclonal Antibodies to 20246.7.2 Xolair (omalizumab, Novartis/Roche)6.7.2.1 Xolair: Sales Forecast 2014-20246.7.3 Cinquil (reslizumab, Teva)6.7.3.1 Cinquil: Sales Forecast 2014-20246.7.4 Mepolizumab (Bosatria, GSK)6.7.4.1 Mepolizumab: Sales Forecast 2014-20246.7.5 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)6.7.5.1 Benralizumab: Sales Forecast 2014-20246.7.6 Lebrikizumab (RG3637, Roche)6.7.6.1 Lebrikizumab: Sales Forecast 2014-20246.7.7 Dupilumab (REGN668, Regeneron/Sanofi)6.7.7.1 Dupilumab: Sales Forecast 2014-20247. Combination Drugs Market 2014-20247. Combination Drugs Market 2014-20247.1 Introduction to Combination Drugs7.1.1 Leading Combination Drugs in 20137.2 Combination Drugs: Market Forec